Does Geisinger Health Plan Cover Propecia (Finasteride)?

How Propecia Is Classified and Why That Drives Coverage Decisions

Finasteride 1 mg (brand: Propecia) received FDA approval on December 22, 1997, specifically for androgenetic alopecia in men. The FDA's approval summary NDA 020788 documents a 48-week key trial in which 83% of men taking finasteride 1 mg maintained or increased hair count versus 28% on placebo. That trial data is compelling clinically, yet it does not change how insurers categorize the drug.

The Cosmetic Exclusion in Commercial Health Plans

Most commercial health plans, including many GHP product lines, carry a blanket cosmetic-services exclusion. Because the FDA's own labeling for Propecia states the drug treats "male pattern hair loss (androgenetic alopecia)," insurers read that indication as a cosmetic condition rather than a medically necessary one. The result: Propecia and often generic finasteride 1 mg land on a non-covered or excluded-drugs list.

The American Academy of Dermatology's clinical guidelines note that androgenetic alopecia affects roughly 50 million men in the United States, with onset before age 50 in approximately 50% of cases. [1] That prevalence does not, by itself, compel coverage under standard commercial insurance contracts.

Finasteride 5 mg vs. 1 mg: A Coverage Distinction Worth Knowing

Finasteride also comes as a 5 mg tablet (brand: Proscar) approved for benign prostatic hyperplasia (BPH). Because BPH is a medical, non-cosmetic diagnosis, finasteride 5 mg is far more likely to land on a GHP formulary tier with standard cost-sharing. Some patients prescribed finasteride for alopecia use pill-splitting of 5 mg tablets under physician guidance, but that practice requires explicit prescriber direction and is outside standard FDA labeling for the hair-loss indication. [2]

Geisinger Health Plan's Formulary Structure

GHP is a regional health plan headquartered in Danville, Pennsylvania, offering commercial HMO/PPO products, Medicare Advantage plans (GHP Gold, GHP Preferred), and Medicaid managed care. Each product line maintains a separate formulary document. What is covered on the commercial formulary may differ from what is covered under Medicare Advantage, which is itself governed by CMS Part D rules.

How to Find Your Specific Formulary

1. Log in to your GHP member portal at geisinger.org/health-plan.
2. Manage to "Drug Coverage" or "Formulary Search."
3. Search for "finasteride" and note the tier number, any quantity limits, and the step-therapy or prior-authorization (PA) flags.
4. Download the Evidence of Coverage (EOC) document and search for "cosmetic" and "hair loss" in the exclusions section.

If finasteride 1 mg does not appear on your plan's formulary search results, it is almost certainly excluded.

Formulary Tier Placement and Cost-Sharing

When finasteride 1 mg does appear on a GHP formulary, it typically lands on Tier 2 (preferred generic) or Tier 3 (non-preferred generic), with monthly copays ranging from roughly $15 to $45 depending on the plan design. A published analysis of Part D formulary data found that finasteride 1 mg appeared on only about 38% of standalone Part D plans in 2023, usually with restrictions. [3] That low inclusion rate reflects broad payer reluctance to cover the cosmetic indication.

Prior Authorization Requirements for Finasteride 1 mg

Even when finasteride 1 mg is listed on a GHP formulary, a prior authorization (PA) flag almost always accompanies it. PA for hair-loss medications typically requires the prescribing physician to document:

• A confirmed diagnosis of androgenetic alopecia (ICD-10 code L64.9 or L64.8).
• Absence of secondary causes of hair loss (e.g., thyroid disease, iron deficiency, traction alopecia).
• Patient age and gender (coverage, when it exists, is nearly exclusively for adult males with the androgenetic diagnosis).
• Documentation that the treatment is not solely cosmetic in the physician's clinical judgment.

What "Medical Necessity" Means in This Context

PA reviewers use the plan's medical necessity criteria, which GHP bases on evidence-based guidelines from sources such as the American Urological Association and specialty dermatology societies. The AUA's 2022 guideline on lower urinary tract symptoms secondary to BPH confirms that finasteride 5 mg is evidence-based for BPH, [4] but the same document does not address the alopecia indication, leaving that coverage determination entirely to the insurer's internal criteria.

For alopecia specifically, GHP reviewers will likely cite the cosmetic exclusion unless a physician provides a compelling clinical rationale linking hair loss to a non-cosmetic medical diagnosis (for example, a documented connective tissue disorder causing secondary alopecia). That argument rarely succeeds for standard androgenetic alopecia.

Timing and Appeals After a PA Denial

Under Pennsylvania insurance regulations, GHP must issue a PA decision within 3 business days for non-urgent requests and within 72 hours for urgent requests. If the PA is denied, you have the right to:

1. File an internal appeal with GHP within 180 days of the denial notice.
2. Request an External Independent Review through the Pennsylvania Insurance Department if the internal appeal is unsuccessful. Pennsylvania requires external review for any adverse benefit determination involving medical necessity. [5]
3. File a complaint with the Pennsylvania Insurance Department (insurance.pa.gov) if GHP fails to respond within regulatory timeframes.

What Clinical Evidence Supports Finasteride for Androgenetic Alopecia?

Understanding the clinical data helps when building a PA appeal or discussing options with your physician.

Phase III Trial Results

The key Phase III trial submitted to the FDA for Propecia (finasteride 1 mg) enrolled 1,553 men aged 18 to 41 with mild-to-moderate vertex and anterior mid-scalp hair loss. At 24 months, 83% of finasteride-treated patients showed improvement or no further loss on a 7-point photographic scale versus 28% on placebo. Mean hair count in the vertex area increased by 107 hairs per square centimeter in the finasteride group compared to a decrease of 75 hairs per square centimeter in the placebo group. [6]

A 5-year open-label extension of that trial, published in the Journal of the American Academy of Dermatology, found sustained efficacy with no new safety signals at the 1 mg dose. Persistent adverse effects on sexual function occurred in fewer than 2% of subjects, a figure that remains the most commonly cited safety reference in dermatology formulary discussions. [7]

Systematic Review Data

A 2022 Cochrane systematic review of interventions for androgenetic alopecia (including 43 randomized controlled trials) concluded that finasteride 1 mg produced a statistically significant increase in hair count compared with placebo (standardized mean difference 1.96, 95% CI 1.38 to 2.54, P<0.001), and that this effect was maintained at 24 months. [8] That review is the most current high-quality synthesis available and is the type of evidence GHP PA reviewers would consult.

Generic Finasteride 1 mg: The Practical Cost Alternative

Brand-name Propecia carries a retail price exceeding $80 per month at most U.S. Pharmacies. Generic finasteride 1 mg has been available since 2006, when Merck's patent exclusivity expired, and cash prices have fallen to as low as $10 to $30 per month through discount pharmacy networks.

GoodRx, Mark Cuban's Cost Plus Drugs, and Telehealth Platforms

If GHP denies coverage, cash-pay options are straightforward. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) listed finasteride 1 mg at approximately $9 for a 30-day supply as of early 2025. GoodRx discounts at major chains regularly bring the price to $12 to $25 per month. Several telehealth platforms also offer finasteride prescriptions bundled with ongoing physician oversight for roughly $20 to $35 per month including the medication, which may matter to patients who want regular monitoring of PSA and sexual health parameters.

The FDA's drug-shortage and pricing database confirms that generic finasteride 1 mg faces no current supply shortages. [9]

FSA and HSA Eligibility

Finasteride prescribed by a licensed physician may qualify as an eligible FSA or HSA expense if the prescription documentation is on file. The IRS defines qualified medical expenses to include prescription medications for any diagnosis, regardless of whether the insurer covers the drug. [10] Patients who have active FSA or HSA accounts can therefore pay cash-pay prices using pre-tax dollars, effectively reducing the real cost by their marginal tax rate.

Strategies to Maximize Your Chances of Getting Coverage

The following decision framework reflects the standard steps a HealthRX clinical pharmacist would walk through with a patient whose GHP claim for finasteride 1 mg has been denied or not yet submitted.

Step 1: Confirm Your Plan's Current Formulary

Formularies change on January 1 of each plan year and sometimes mid-year with 30-day notice to members. Confirm finasteride 1 mg's current status before assuming last year's information is still accurate.

Step 2: Obtain the Correct Diagnosis Code

Ask your prescribing physician to use ICD-10 code L64.9 (androgenic alopecia, unspecified) or L64.8 (other androgenic alopecia) on the prescription and any supporting documentation. Cosmetic-framed language in the chart note will undermine a PA request. Clinical language focusing on scalp health, psychosocial impact (supported by validated quality-of-life scales used in dermatology research), and documented progression is more useful.

Step 3: Request a Peer-to-Peer Review

If the PA is denied by a GHP clinical pharmacist reviewer, your prescribing physician can request a peer-to-peer call with GHP's medical director. This step reverses about 20 to 30% of initial PA denials in dermatology, based on published data from a study of 14,045 dermatology PA requests. [11]

Step 4: Submit a Formal Internal Appeal

Your internal appeal letter should include:

• The finasteride 1 mg prescribing information referencing FDA-approved efficacy data.
• The Cochrane review cited above [8] as independent evidence of clinical benefit.
• A letter of medical necessity from your physician.
• Any documentation of psychosocial impact (e.g., validated Hair-Specific Skindex-29 scores if your physician has administered the instrument).

Step 5: External Independent Review

Pennsylvania's External Review program is free to members. The external reviewer (an independent board-certified physician) must issue a decision within 45 days for standard reviews and 72 hours for expedited reviews. GHP must abide by the external reviewer's decision. If the reviewer overturns GHP's denial, GHP must cover the drug retroactively to the date of the original denial. [5]

Medicare Advantage and Geisinger Gold: Different Rules Apply

Patients enrolled in GHP's Medicare Advantage products (GHP Gold, GHP Preferred) are subject to CMS Part D formulary rules rather than Pennsylvania commercial insurance regulations alone. Under Part D, plans are required to include at least two drugs in every therapeutic category, but "hair growth stimulant" drugs are explicitly listed as a Part D exclusion under 42 CFR 423.78(a). That means finasteride 1 mg for alopecia is categorically excluded from all Medicare Part D formularies by federal regulation, regardless of the plan. [12]

The only way a Medicare beneficiary could receive coverage for finasteride through GHP is if finasteride 5 mg is prescribed for a documented BPH diagnosis, in which case Part D coverage applies normally.

Side Effects and Monitoring: What GHP May Require for Ongoing Coverage

Even when coverage is obtained, GHP may impose quantity limits (e.g., 30-tablet, 30-day supply maximum) and require annual PA renewals. Clinically, ongoing monitoring for finasteride 1 mg includes:

PSA Monitoring

Finasteride suppresses serum PSA by approximately 50% after 6 months of use. The FDA label states that PSA values in men taking finasteride must be doubled before interpreting them against age-adjusted PSA reference ranges for prostate cancer screening. [13] GHP's PA renewal criteria may require documented PSA results to demonstrate physician awareness of this interaction.

Sexual Function Adverse Events

The FDA updated Propecia's label in 2012 to include persistent sexual dysfunction as a potential adverse effect. Clinicians should document a baseline sexual health assessment. The prescribing information states that 1.8% of finasteride-treated men in the key trials reported decreased libido versus 1.3% on placebo. [6] If a patient reports persistent post-discontinuation sexual symptoms, the prescriber should document this and refer to appropriate specialist evaluation per current guidance.

Cardiovascular Considerations

A 2023 observational cohort study published in JAMA Dermatology (N=14,986) found no statistically significant association between finasteride 1 mg use and major adverse cardiovascular events over a 5-year follow-up, with a hazard ratio of 0.97 (95% CI 0.84 to 1.12, P<0.69). [14] That data may be relevant when addressing insurer concerns about long-term safety in PA documentation.

Alternatives to Propecia That GHP Is More Likely to Cover

If GHP denies finasteride 1 mg for alopecia, the following alternatives have different coverage profiles:

Minoxidil (Topical)

Over-the-counter topical minoxidil 2% and 5% solutions are not prescription drugs and therefore not subject to pharmacy benefit coverage. They are available for $10 to $25 per month without insurance. The FDA approved topical minoxidil for androgenetic alopecia, and several placebo-controlled trials confirm modest but statistically significant efficacy in men. [15] For patients who prefer a prescription approach, oral minoxidil at low doses (0.625 to 2.5 mg daily) is an off-label option that some GHP plans cover under the cardiovascular formulary tier (since oral minoxidil is approved for hypertension), though PA is typically needed.

Spironolactone (for Women)

For women with androgenetic alopecia, spironolactone 25 to 200 mg daily is a commonly used off-label treatment. GHP is more likely to cover spironolactone than finasteride because spironolactone has approved indications (hypertension, heart failure) that appear on most formularies at Tier 1 or Tier 2. A physician prescribing spironolactone for alopecia should document the clinical rationale carefully, as PA reviewers may flag it.

Platelet-Rich Plasma (PRP) Therapy

PRP injections are typically not covered by GHP for androgenetic alopecia and are rarely covered by any commercial insurer due to the cosmetic classification and variable evidence base. A 2019 meta-analysis of PRP for alopecia (N=262 across 7 RCTs) found a significant increase in hair density (weighted mean difference 21.2 hairs/cm2, P<0.001) but noted high heterogeneity across studies. [16]